ELDN Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
21.7M
-5.2%
22.9M
+8.0%
21.2M
-1.4%
21.5M
+12.7%
19.1M
R&D
17.8M
-2.6%
18.2M
+6.0%
17.2M
-1.7%
17.5M
+16.8%
15.0M
SG&A
3.9M
-15.7%
4.6M
+16.4%
4.0M
-0.2%
4.0M
-2.6%
4.1M
Operating Income
-21672000
+5.2%
-22869000
-8.0%
-21181000
+1.4%
-21484000
-12.7%
-19070000
EBITDA
-21672000
+5.2%
-22869000
-8.0%
-21181000
+1.4%
-21484000
-12.7%
-19070000
Net Income
-3933000
+87.6%
-31630000
+18.9%
-39025000
-273.6%
-10447000
+40.2%
-17459000
EPS (Basic)
$-0.03
+88.9%
$-0.27
+18.2%
$-0.33
-135.7%
$-0.14
+33.3%
$-0.21
EPS (Diluted)
$-0.03
+88.9%
$-0.27
+18.2%
$-0.33
-135.7%
$-0.14
+33.3%
$-0.21
Shares (Diluted)
114.7M
+1.0%
113.6M
+1.1%
112.4M
+17.2%
95.9M
+24.3%
77.2M
Eledon Pharmaceuticals (ELDN) — Financials